IFCC certifies EKF Diagnostics point-of-care analyser

Friday, 10 January, 2014

Global diagnostics company EKF Diagnostics has announced that its Quo-Lab HbA1c point-of-care analyser has successfully achieved International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) certification. The analyser offers laboratory-accurate results from just 4 µL of blood with a user-friendly interface.

Glycated haemoglobin (HbA1c) testing is globally recognised as the gold standard in monitoring of diabetic patients, enabling more complete control of their disease management. The IFCC maintains the JCTLM (Joint Committee for Traceability in Laboratory Medicine) endorsed reference measurement procedure for HbA1c, accepted worldwide as the analytical control for traceability of HbA1c measurement.

To participate in the program, manufacturers are required to register and report the results of 24 samples (two per month) from across the measurement range. The samples are supplied by an IFCC reference laboratory.

“The awarding of this certification allows us to report results traceable to the IFCC reference method for quantitative determination of HbA1c,” said Gavin Jones, diabetes product manager, EKF Diagnostics. “Together with the existing NGSP certification we achieved from 2012, the IFCC award demonstrates conclusively that Quo-Lab meets all of the demanding standards set by independent certifying bodies.”

Source

Related News

L'Oréal-UNESCO For Women In Science Fellows announced for ANZ

This year's program honours four women who are reshaping what leadership in research looks...

Peter Beattie appointed Chair of Brandon BioCatalyst

Brandon BioCatalyst has announced new board appointments to continue the scaling of Australian...

Virologist receives GSK Award for AI-based disease detection

Professor Edward Holmes has received the 2025 GSK Award for Research Excellence for his use of...


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd